Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
The role of blood tumor marker measurement (using a biochemical index score and c-erbB2) in directing chemotherapy in metastatic breast cancer
Autore:
Cheung, KL; Pinder, SE; Paish, C; Sadozye, AH; Chan, SY; Evans, AJ; Blamey, RW; Robertson, JFR;
Indirizzi:
City Hosp, Professorial Unit Surg, Dept Surg, Nottingham NG5 1PB, England City Hosp Nottingham England NG5 1PB t Surg, Nottingham NG5 1PB, England City Hosp, Dept Histopathol, Nottingham NG5 1PB, England City Hosp Nottingham England NG5 1PB pathol, Nottingham NG5 1PB, England City Hosp, Dept Clin Oncol, Nottingham NG5 1PB, England City Hosp Nottingham England NG5 1PB Oncol, Nottingham NG5 1PB, England City Hosp, Dept Radiol, Nottingham NG5 1PB, England City Hosp NottinghamEngland NG5 1PB Radiol, Nottingham NG5 1PB, England
Titolo Testata:
INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS
fascicolo: 3, volume: 15, anno: 2000,
pagine: 203 - 209
SICI:
0393-6155(200007/09)15:3<203:TROBTM>2.0.ZU;2-L
Fonte:
ISI
Lingua:
ENG
Soggetto:
OBJECTIVE MEASUREMENT; THERAPEUTIC RESPONSE; SERUM;
Keywords:
blood tumor marker; CA15.3; CEA; ESR; biochemical index score; c-erbB2; chemotherapy; advanced breast cancer; metastatic breast cancer;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
19
Recensione:
Indirizzi per estratti:
Indirizzo: Cheung, KL City Hosp, Professorial Unit Surg, Dept Surg, Hucknall Rd, Nottingham NG5 1PB, England City Hosp Hucknall Rd Nottingham England NG5 1PB 1PB, England
Citazione:
K.L. Cheung et al., "The role of blood tumor marker measurement (using a biochemical index score and c-erbB2) in directing chemotherapy in metastatic breast cancer", INT J B MAR, 15(3), 2000, pp. 203-209

Abstract

The role of blood tumor markers in monitoring response in advanced breast cancer is established in endocrine therapy and standard chemotherapy. This study examines marker levels in patients receiving new chemotherapy regimens. Thirty patients were recruited into two multicenter trials in which docetaxel-based regimens were used in 15 patients. The other 15 received doxorubicin-based regimens. Biochemical response calculated from a score using CA15.3, CEA and ESR was compared with UICC response. Marker changes at 2, 4 and 5 months correlated with UICC response at 3, 4(1/2) and 6 months, respectively (p < 0.03). Eleven patients achieved both clinical/radiological and biochemical response at the end of treatment; markers had not yet returned to below cutoffs in seven, suggesting a possible advantage to continue chemotherapy. No patient showed a biochemical response whilst judged clinically/radiologically progressive. Nineteen patients had progressed either clinically/radiologically or biochemically at six months; of these, eight showed progression assessed earlier by markers so that a median of four cycles of chemotherapy could have been saved. Measurements of serum c-erbB2 showed a correlation with tissue c-erbB2 staining in the primary tumor (p < 0.003). Among the patients with positive tissue staining, sequential changes in serum c-erbB2 completely paralleled initial response.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 26/09/20 alle ore 13:19:32